Ascioglu S, de Pauw BE, Meis JF: Prophylaxis and treatmentof fungal infections associated with haematological malignancies. Int J Antimicrob Agents. 2000, 15: 159-168. 10.1016/S0924-8579(00)00159-X.
Article
CAS
PubMed
Google Scholar
Bow EJ, Laverdière M, Lussier N, Rotstein C, Cheang MS, Ioannou S: Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta-analysis of randomized controlled clinical trials. Cancer. 2002, 94: 3230-3246. 10.1002/cncr.10610.
Article
CAS
PubMed
Google Scholar
Robenshtok E, Gafter-Gvili A, Goldberg E, Weinberger M, Yeshurun M, Leibovici L, et al: Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol. 2007, 25: 5471-5489. 10.1200/JCO.2007.12.3851.
Article
CAS
PubMed
Google Scholar
Maertens J, Buve K, Anaissie E: Broad-spectrum antifungal prophylaxis in patients with cancer at high risk for invasive mold infections: counterpoint. J Natl Compr Canc Netw. 2008, 6: 183-189.
PubMed
Google Scholar
Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, et al: Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis. 2003, 37: 1172-1177. 10.1086/378745.
Article
PubMed
Google Scholar
Enoch DA, Ludlam HA, Brown NM: Invasive fungal infections: a review of epidemiology and management options. J Med Microbiol. 2006, 55: 809-818. 10.1099/jmm.0.46548-0.
Article
CAS
PubMed
Google Scholar
Zaoutis TE, Heydon K, Chu JH, Walsh TJ, Steinbach WJ: Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics. 2006, 117: e711-e716. 10.1542/peds.2005-1161.
Article
PubMed
Google Scholar
Safdar A: Difficulties with fungal infections in acute myelogenous leukemia patients: immune enhancement strategies. Oncologist. 2007, 12 (suppl 2): 2-6.
CAS
PubMed
Google Scholar
Frampton JE, Scott LJ: Posaconazole: a review of its use in the prophylaxis of invasive fungal infections. Drugs. 2008, 68: 993-1016. 10.2165/00003495-200868070-00008.
Article
CAS
PubMed
Google Scholar
Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, et al: Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007, 356: 348-359. 10.1056/NEJMoa061094.
Article
CAS
PubMed
Google Scholar
Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, et al: Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007, 356: 335-347. 10.1056/NEJMoa061098.
Article
CAS
PubMed
Google Scholar
Maertens JA, Frere P, Lass-Florl C, Heinz W, Cornely OA: Primary antifungal prophylaxis in leukaemia patients. Eur J Cancer Suppl. 2007, 5: 43-48.
Article
CAS
Google Scholar
Meunier F, Lukan C: The First European Conference on Infections in Leukaemia-ECIL1: a current perspective. Eur J Cancer. 2008, 44: 2112-2117. 10.1016/j.ejca.2008.07.008.
Article
PubMed
Google Scholar
National Comprehensive Cancer Network: Prevention and treatment of cancer-related infection. NCCN Clinical Practice Guidelines in Oncology. V.1.2008, [http://www.nccn.org/professionals/physician_gls/PDF/infections.pdf]
Walsh T, Anaissie E, Denning D, Herbrecht R, Kontoyiannis D, Marr K, et al: Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infectious Dis. 2008, 46: 327-360. 10.1086/525258.
Article
CAS
Google Scholar
Ess SM, Schneeweiss S, Szucs TD: European healthcare policies for controlling drug expenditure. Pharmaco Econ. 2003, 21: 89-103. 10.2165/00019053-200321020-00002.
Article
Google Scholar
Chambers M, Hutton J, Nuitjen M: Budget impact analysis for health technology appraisal: development and application within the NICE appraisal process. J Clin Excellence. 2002, 4: 203-206.
Google Scholar
Slavin M, Fastenau J, Sukarom I, Mavros P, Crowley S, Gerth WC: Burden of hospitalization of patients with Candida and Aspergillus infections in Australia. Int J Infect Dis. 2004, 8: 111-120. 10.1016/j.ijid.2003.05.001.
Article
PubMed
Google Scholar
Olaechea PM, Palomar M, León-Gil C, Alvarez-Lerma F, Jordá R, Nolla-Salas J, et al: EPCAN Study Group. Economic impact of Candida colonization and Candida infection in the critically ill patient. Eur J Clin Microbiol Infect Dis. 2004, 23: 323-330. 10.1007/s10096-004-1104-x.
Article
CAS
PubMed
Google Scholar
Alvarez-Lerma F, Nicolás-Arfelis JM, Rodríguez-Borregán JC, Díaz-Regañón J, Sa-Borges M, García-López F, et al: Clinical use and tolerability of voriconazole in the treatment of fungal infections in critically ill patients. J Chemother. 2005, 17: 417-427.
Article
CAS
PubMed
Google Scholar
Wenzel R, Del Favero A, Kibbler C, Rogers T, Rotstein C, Mauskopf J, et al: Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients. J Antimicrob Chemother. 2005, 55: 352-361. 10.1093/jac/dkh535.
Article
CAS
PubMed
Google Scholar
Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH: Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006, 106: 2258-2266. 10.1002/cncr.21847.
Article
PubMed
Google Scholar
Cagatay AA, Cosan F, Karadeniz A, Besısık SK, Ozsut H, Nalcaci M, et al: The clinical and pharmacoeconomic analysis of invasive aspergillosis in adult patients with haematological diseases. Mycoses. 2008, 51: 328-335. 10.1111/j.1439-0507.2007.01483.x.
Article
PubMed
Google Scholar
Wingard JR, Kubilis P, Lee L, Yee G, White M, Walshe L, et al: Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergilosis. Clin Infect Dis. 1999, 29: 1402-1407. 10.1086/313498.
Article
CAS
PubMed
Google Scholar
Wingard JR, Herbrecht R, Mauskopf J, Schlamm HT, Marciniak A, Roberts CS: Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis. Transpl Infect Dis. 2007, 9: 182-188. 10.1111/j.1399-3062.2007.00210.x.
Article
CAS
PubMed
Google Scholar
Penack O, Reinhold T, Thiel E, Blau IW: Cost-benefit assessment of antifungal prophylaxis with liposomal amphotericin B in neutropenic patients. Onkologie. 2007, 30: 621-626. 10.1159/000110070.
CAS
PubMed
Google Scholar
de Vries R, Daenen S, Tolley K, Glasmacher A, Prentice A, Howells S, et al: Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections. PharmacoEconomics. 2008, 26: 75-90. 10.2165/00019053-200826010-00007.
Article
CAS
PubMed
Google Scholar
Stam WB, O'Sullivan AK, Rijnders B, Lugtenburg E, Span LF, Janssen JJ, et al: Economic evaluation of posaconazole versus standard azole prophylaxis in high risk neutropenic patients in the Netherlands. Eur J Haematol. 2008, 81: 467-474. 10.1111/j.1600-0609.2008.01141.x.
Article
PubMed
Google Scholar
López-Bastida J, Oliva J, Antoñanzas F, García-Altés A, Gisbert R, Mar J, Puig-Junoy J: Spanish recommendations on economic evaluation of health technologies. Eur J Health Econ. 2010, 11: 513-520. 10.1007/s10198-010-0244-4.
Article
PubMed
Google Scholar
Briggs A, Sculpher M: An introduction to Markov modelling for economic evaluation. Pharmaco Econ. 1998, 13: 397-409. 10.2165/00019053-199813040-00003.
Article
CAS
Google Scholar
Spanish National Statics Institute. [http://www.ine.es]
National Cancer Institute (NCI): SEER Cancer Statistics Review 1975-2003. Age-adjusted SEER incidence and US death rates and 5-year relative survival rates. 2006
Google Scholar
Kantarjian H, Beran M, Cortes J, O'Brien S, Giles F, Pierce S, et al: Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer. 2006, 106: 1099-1109. 10.1002/cncr.21699.
Article
CAS
PubMed
Google Scholar
General Spanish Council of Pharmacists. BOT database of pharmaceutical prices. [http://www.botplusweb.portalfarma.com]
Gisbert R, Brosa M, [CD-ROM database]: Healthcare Reference Costs. 2005, Barcelona: Centre d'Estudis en Economı'a de la Salut i de la Política Social, SOIKOS Version 2.2
Google Scholar
Grau Cerrato S, Mateu de Antonio J, Soto Alvarez J, Muñoz Jareño MA, Salas Sánchez E, Marín-Casino M, et al: Economic evaluation of voriconazole versus amphotericin B in the treatment of invasive aspergilosis. Farm Hosp. 2005, 29: 5-10. 10.1016/S1130-6343(05)73629-1.
Article
CAS
PubMed
Google Scholar
Gold MR, Siegel JE, Russell LB, Weinstein MC: Cost-effectiveness in Health and Medicine. 1996, New York: Oxford University Press
Google Scholar
Sacristán JA, Oliva J, Del Llano J, Prieto L, Pinto JL: What is an efficient health technology in Spain?. Gac Sanit. 2002, 16: 334-343.
Article
PubMed
Google Scholar
Collins CD, Ellis JJ, Kaul DR: Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia. Am J Health-Syst Pharm. 2008, 65: 2237-2243. 10.2146/ajhp070588.
Article
CAS
PubMed
Google Scholar
O'Sullivan AK, Pandya A, Papadopoulos G, Thompson D, Langston A, Perfect J, Weinstein MC: Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States. Value Health. 2009, 12: 666-673. 10.1111/j.1524-4733.2008.00486.x.
Article
PubMed
Google Scholar
Greiner RA, Meier Y, Papadopoulos G, O'Sullivan AK, Imhof A: Cost-effectiveness of posaconazole compared with standard azole therapy for prevention of invasive fungal infections in patients at high risk in Switzerland. Oncology. 2010, 78: 172-180.
Article
CAS
PubMed
Google Scholar
Tahami AA, O'Sullivan AK, Papadopoulos G: Posaconazole versus standard azole therapy in the prophylaxis against invasive fungal infections among high-risk neutropenic patients in Canada: a cost-effectiveness analysis. 18th European Congress of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Barcelona, Spain, 19-22. 2008, April . Abstract number: P1029
Google Scholar
Thalheimer M, Cornely OA, Hoppe-Tichy T, Schuler U, Knoth H, Kiehl M, et al: Pharmaco-economic analyis of posaconazole versus standard azole prophylaxis in high-risk neutropenic AML/MDS patients in Germany. 18th European Congress of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Barcelona, Spain, 19-22. 2008, April . Abstract number: P1031
Google Scholar